Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 28;55(7):320.
doi: 10.3390/medicina55070320.

The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population

Osama Abo Alrob  1 , Sayer Alazzam  2 , Karem Alzoubi  3 , Mohammad B Nusair  4 , Haneen Amawi  5 , Reema Karasneh  6 , Abeer Rababa'h  7 , Mohammad Nammas  8
Affiliations

The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population

Osama Abo Alrob et al. Medicina (Kaunas). .

Abstract

Objectives: The aim of this study was to determine the incidence of metabolic syndrome in patients treated with second-generation antipsychotics (SGAs). Methods: In this retrospective study, we reviewed patients' electronic medical records (EMRs) of all patients who received one SGA for at least six months, excluding patients who were taking other medications that are associated with significant effect on metabolic syndrome. Relevant clinical information was collected prior to starting the SGA and after six months of continuous use of the same SGA. Results: A total of 91 patients were included in the study. The majority of patients (72%) were diagnosed with schizophrenia. After six months of taking the SGA, 44% of patients experienced elevated systolic pressure, 54.9% had elevated triglyceride, and 31.9% had impaired glucose levels (p value < 0.05). Prior to initiating SGA therapy, 14.3% of patients had metabolic syndrome, while 37.4% had metabolic syndrome after six months of therapy, and it was more prominent in males compared to female patients (p value < 0.05). Conclusion: This study found a strong correlation between SGA use and the appearance of metabolic alterations, such as weight gain, glucose intolerance, and increased triglyceride levels. These findings highlight the importance of assessing metabolic deregulations to minimize SGA associated metabolic abnormalities.

Keywords: atypical antipsychotics; metabolic syndrome; second-generation antipsychotics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Plasma Triglyceride and BMI variation across genders six months post-SGAs therapy.
Figure 2
Figure 2
Diagram that illustrates the effect of SGA medications use on metabolic syndrome parameters in the study population.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486. - DOI - PubMed
    1. Mohan V., Parikh R.M., Parikh R., Parikh R.M. Changing definitions of metabolic syndrome. Indian J. Endocrinol. Metab. 2012;16:7–12. - PMC - PubMed
    1. International Diabetes Federation The IDF consensus worldwide definition of the metabolic syndrome. IDF Commun. 2006:1–23.
    1. Sherling D.H., Perumareddi P., Hennekens C.H. Metabolic syndrome: Clinical and policy implications of the new silent killer. J. Cardiovasc. Pharmacol. Ther. 2017;22:365–367. - PubMed
    1. Oda E. Metabolic syndrome: Its history, mechanisms, and limitations. Acta Diabetol. 2012;49:89–95. doi: 10.1007/s00592-011-0309-6. - DOI - PubMed

MeSH terms